Impact of a carrageenan gel on viral load of genital human papillomavirus infections in sexually active women: Findings from the Carrageenan‐gel Against Transmission of Cervical Human papillomavirus (CATCH) trial

• Published in: Journal of medical virology Vol. 96; no. 4; pp. e29604 - n/a
• Main Authors: Laurie, Cassandra, El‐Zein, Mariam, Tota, Joseph E., Tellier, Pierre‐Paul, Coutlée, François, Burchell, Ann N., Franco, Eduardo L.
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01-04-2024
• Subjects: Carrageenan; Carrageenans; Disease transmission; female; gels; Human papillomavirus; Infections; Polymerase chain reaction; Statistical analysis; viral load; viral load; female; carrageenan; gels; human papillomavirus
• ISSN: 0146-6615; 1096-9071
• DOI: 10.1002/jmv.29604

Previous research has shown that women's use of a carrageenan gel reduces the risk of acquiring genital human papillomavirus (HPV) infections but does not help to clear existing ones. Although gel use may not result in complete clearance, it may decrease the viral load of HPV infections. We tested this hypothesis in the Carrageenan‐gel Against Transmission of Cervical Human papillomavirus (CATCH) randomized controlled trial. Participants of the CATCH study were selected for viral load testing if they had completed the first four study visits and tested positive for HPV42 or HPV51 in at least one of these visits. HPV42 and HPV51 were chosen as they were among the most abundant low‐ and high‐risk types, respectively, in the study sample. We measured viral load with a type‐specific real‐time polymerase chain reaction. Results were displayed using summary statistics. Of 461 enrolled participants, 39 were included in the HPV42 analysis set and 56 in the HPV51 analysis set. The median time between visits 1 and 4 was 3.7 months. The viral load (copies/cell) of HPV42 ranged from <0.001 to 13 434.1, and that of HPV51 from <0.001 to 967.1. The net median change in HPV42 viral load over all four visits was −1.04 copies/cell in the carrageenan and −147 copies/cell in the placebo arm (Wilcoxon rank sum test, p = 0.26). There was no net median change in HPV51 viral load over all four visits in either arm (p = 0.45). The use of a carrageenan‐based gel is unlikely to reduce the viral load of HPVs 42 or 51.